Home » Newsletters » BioWorld Science

BioWorld Science

June 1, 2016

View Archived Issues

L-Citrulline safe but has rapid clearance in patients with sickle cell disease

Atlanthera patents anticancer agents

Chinese scientists disclose cytidine dimers for the treatment of cancer

University College Cardiff Consultants develops AR antagonists

Esteve announces dual sigma1 and mu-opioid receptor ligands

Boehringer Ingelheim and Inventiva announce research and drug discovery collaboration

Bristol-Myers Squibb presents HIV maturation inhibitors

BioMarin withdraws Kyndrisa MAA, discontinues development of follow-on products

Nuplazid now available for prescription in the U.S.

Studies with CM-4620 in pancreatitis models suggest CRAC inhibition is beneficial

Soligenix's SGX-943 gets FDA fast track designation

FDA grants emergency use authorization to Idylla Ebola Virus Triage Test

Amicus's migalastat hydrochloride obtains first approval in Europe

Teva receives complete response letter for SD-809 for the treatment of chorea associated with HD

Contravir Pharmaceuticals to buy Ciclofilin Pharmaceuticals

FDA approves Teflaro in pediatric patients

Chugai licenses SA-237 rights to Roche

Imbruvica approved in E.U. as first-line treatment for CLL

FDA accepts for review sNDA for Vertex's Orkambi

Phase III study of patritumab in NSCLC not to continue

ASCL1 may be useful as a biomarker for lung adenocarcinoma in smokers

EMA committee supports expanding approval of Tysabri

Trevicta 3-monthly injection approved for schizophrenia in E.U.

Phase II study of CymaBay's MBX-8025 shows proof of concept

FDA accepts for filing Radius Health's NDA for abaloparatide-SC

Lexicon's NDA for telotristat accepted for filing by FDA

Brentuximab vedotin receives FDA orphan designation for adult T-cell leukemia/lymphoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...